Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
Recent news highlights that the Factor XI inhibitor space is emerging as the next significant advancement in cardiovascular care, and at Ribo, we are proud to be at the forefront of this development. FXI inhibition has the potential to address a substantial unmet need and to represent a breakthrough in anti-coagulation therapy for millions of […]
Ribo announces the publication of a scientific paper of our liver-targeted siRNA against Factor XI, which is being developed as a potential breakthrough treatment for thrombosis
RBD4059 is a GalNAc-conjugated small-interfering RNA (siRNA) drug independently developed by Suzhou Ribo Life Science. Ltd (Ribo) based on the RIBO-GalSTARTM liver targeting technology platform. RBD4059 achieves antithrombotic effects by silencing the FXI protein expression by RNA interference and thereby blocking the activation of the endogenous coagulation pathway. The results of the current preclinical study […]
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
Suzhou Ribo Life Science and Ribocure AB are excited to share that we have achieved a key pre-clinical milestone in our siRNA programs, less than a year into our collaboration with Boehringer Ingelheim. These achievements highlight the strength of Boehringer Ingelheim’s expertise in MASH and validate the power of the Ribo platform and organization. We […]
Ribo’s siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia
On October 28, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3. The trial will evaluate efficacy and safety in patients with mixed dyslipidemia. A randomized, […]
First Patient Dosed at Ribocure Clinic
With the ambition to become a world-leading clinical oligonucleotide research company, Ribocure Pharmaceuticals AB has established Ribocure Clinic, to focus on high-quality Proof of Principle Ph2 studies. The clinic has now dosed its first patient in a Phase 2 study using the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, RBD4059. Ribocure Clinic, […]
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) have entered a strategic partnership with Pheiron to leverage its cutting-edge AI platform, PheironGPS, in Ribo’s discovery and development of RNA-based therapeutics. This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology. PheironGPS […]
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
On September 10, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a first-in-human (FIH) Phase I clinical trial in Sweden with the siRNA drug, RBD7007 targeting C5. This is a first-in-human (FIH) phase 1 trial to assess the safety, tolerability, and […]
Ribo presented the first clinical data from our completed Ph1 study of the world’s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.
We thank the European Society of Cardiology #ESC Congress, session chairs, and all participants in the session for the opportunity and attention. We look forward to continuing the further clinical development of RBD4059 based on our Phase 1 results. “We are excited to have progressed world’s first and most advanced FXI siRNA program, now into […]
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the world’s first siRNA drug targeting Factor XI: RBD4059
On May 27, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the world’s first and most advanced anti-thrombotic siRNA drug, RBD4059 targeting FXI. The trial will evaluate safety, pharmacokinetics and pharmacodynamics of its […]
Join us in celebrating Clinical Trials Day!
Today we highlight the Clinical Trials Day and the importance of clinical research at Ribocure Pharmaceuticals and Ribocure Clinic. Ribocure Clinic is our specialized clinical trial unit with highly trained medical research staff for Phase 2 trials in cardiovascular, pulmonary, renal and liver disease, where advanced imaging and functional assessments are applied. Read more about […]
